Literature DB >> 3921546

Effects of monensin on the synthesis, transport, and intracellular degradation of proteoglycans in rat ovarian granulosa cells in culture.

M Yanagishita, V C Hascall.   

Abstract

Rat ovarian granulosa cells, isolated from immature female rats 48 h after stimulation with 5 IU of pregnant mare's serum gonadotropin, were maintained in culture. The effects of monensin, a monovalent cationic ionophore, on various aspects of proteoglycan metabolism were studied by metabolically labeling cultures with [35S]sulfate, [3H]glucosamine, or [3H]glucose. Monensin inhibited post-translational modification of both heparan sulfate (HS) proteoglycans and dermatan sulfate (DS) proteoglycans, resulting in decreased synthesis of completed proteoglycans [( 35S]sulfate incorporation decreased to 10% of control by 30 microM monensin, with an ED50 approximately 1 microM). Proteoglycans synthesized in the presence of monensin showed undersulfation of both DS and HS glycosaminoglycans and altered N-linked and O-linked oligosaccharides, suggesting that the processing of all sugar moieties is closely associated. Monensin caused a decrease in the endogenous sugar supply to the UDP-N-acetylhexosamine pool as indicated by an increased 3H incorporation into DS chains [( 3H]glucosamine as precursor) in spite of the decrease in glycosaminoglycan synthesis. Monensin reduced and delayed transport of both secretory and membrane-associated proteoglycans from the Golgi complex to the cell surface. It took 2-4 min for newly labeled proteoglycans to reach the main transport process inhibited by monensin. Monensin at 30 microM did not prevent internalization of cell surface 35S-labeled proteoglycans but almost completely inhibited their intracellular degradation to free [35S]sulfate (ED50 approximately 1 microM), resulting in intracellular accumulation of both DS and HS proteoglycans. Pulse-chase experiments demonstrated that one of the intracellular degradation pathways involving proteolysis of both DS and HS proteoglycans and limited endoglycosidic cleavage of HS continued to operate in the presence of monensin. These results suggest that the intracellular degradation of proteoglycans involve both acidic and nonacidic compartments with monensin inhibiting those processes that normally occur in such acidic compartments as endosomes or lysosomes by raising their pH.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921546

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Structure and function of heparan sulphate proteoglycans.

Authors:  J T Gallagher; M Lyon; W P Steward
Journal:  Biochem J       Date:  1986-06-01       Impact factor: 3.857

2.  Protection by glycine against chemical ischemia produced by cyanide in cultured hepatocytes.

Authors:  I Sakaida; A Nagatomi; K Okita
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

3.  Synthesis of hyaluronate in cultured bovine articular cartilage.

Authors:  C K Ng; C J Handley; R M Mason; H C Robinson
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

4.  Brefeldin A inhibits the endocytosis of plasma-membrane-associated heparan sulphate proteoglycans of cultured rat ovarian granulosa cells.

Authors:  L Uhlin-Hansen; M Yanagishita
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

5.  The effect of monensin on thyroglobulin secretion. Studies with isolated follicles from pig thyroids.

Authors:  P Ring; U Björkman; V Johanson; R Ekholm
Journal:  Cell Tissue Res       Date:  1987-04       Impact factor: 5.249

Review 6.  Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity.

Authors:  H H Mollenhauer; D J Morré; L D Rowe
Journal:  Biochim Biophys Acta       Date:  1990-05-07

7.  The exploitation of human glycans by Group A Streptococcus.

Authors:  Anuk D Indraratna; Arun Everest-Dass; Danielle Skropeta; Martina Sanderson-Smith
Journal:  FEMS Microbiol Rev       Date:  2022-05-06       Impact factor: 15.177

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.